Aortic stiffness and systemic inflammation changes predict clinical response to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration

[1]  Yunlian Xue,et al.  A Meta-Analysis of Cardiovascular Events Associated with Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion , 2020, Current eye research.

[2]  P. Nilsson,et al.  Association of Estimated Pulse Wave Velocity With Survival , 2019, JAMA network open.

[3]  C. Vlachopoulos,et al.  Effect of Ticagrelor Versus Clopidogrel on Aortic Stiffness in Patients With Coronary Artery Disease , 2019, Journal of the American Heart Association.

[4]  D. Hodge,et al.  Association of Intravitreal Anti–Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration , 2019, JAMA ophthalmology.

[5]  Jinfeng Xu,et al.  Effect of ranibizumab on levels of IL-6 and VEGF in peripheral blood and aqueous humor of glaucoma rat model and association of IL-6 and VEGF with optic nerve damage , 2018, Experimental and therapeutic medicine.

[6]  A. D. den Hollander,et al.  Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration , 2018, Molecular Diagnosis & Therapy.

[7]  R. Danesi,et al.  Clinical pharmacology of intravitreal anti-VEGF drugs , 2018, Eye.

[8]  E. Zenteno,et al.  Age-Related Macular Degeneration: New Paradigms for Treatment and Management of AMD , 2018, Oxidative medicine and cellular longevity.

[9]  C. Vlachopoulos,et al.  The effect of TNF-a antagonists on aortic stiffness and wave reflections: a meta-analysis , 2018, Clinical Rheumatology.

[10]  F. Ruschitzka,et al.  SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration , 2017, Ophthalmologica.

[11]  H. Kawashima,et al.  Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy , 2017, British Journal of Ophthalmology.

[12]  Douglas S. Lee,et al.  Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. , 2017, Cancer treatment reviews.

[13]  R. Guymer,et al.  Age-Related Macular Degeneration and Mortality: A Systematic Review and Meta-Analysis , 2017, Ophthalmic epidemiology.

[14]  M. DeAngelis,et al.  Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors , 2016, Eye and Vision.

[15]  B. Vote,et al.  Effect of intravitreal anti-vascular endothelial growth factor agents on blood pressure - a cross-sectional analysis. , 2016, Journal of hypertension.

[16]  M. Ergun,et al.  CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration , 2016, Ophthalmic Research.

[17]  N. Bressler,et al.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. , 2016, Ophthalmology.

[18]  T. Shiba,et al.  Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Drugs in Patients with Exudative Age-Related Macular Degeneration , 2016, Ophthalmologica.

[19]  V. Aboyans,et al.  The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. , 2015, Atherosclerosis.

[20]  F. Gueyffier,et al.  Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. , 2014, JAMA ophthalmology.

[21]  Francesco Bandello,et al.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) , 2014, British Journal of Ophthalmology.

[22]  S. Grover,et al.  Aqueous Interleukin-6 Levels Are Superior to Vascular Endothelial Growth Factor in Predicting Therapeutic Response to Bevacizumab in Age-Related Macular Degeneration , 2014, Journal of ophthalmology.

[23]  R. Avery,et al.  Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD , 2014, British Journal of Ophthalmology.

[24]  Ronald Klein,et al.  Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study. , 2014, JAMA ophthalmology.

[25]  R. Klein,et al.  Age-related macular degeneration and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. , 2012, Ophthalmology.

[26]  M. Stewart.  The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. , 2012, Mayo Clinic proceedings.

[27]  P. Mitchell,et al.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis , 2010, BMC ophthalmology.

[28]  Mark Michels,et al.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.

[29]  J. McNeil,et al.  Novel measures of cardiovascular health and its association with prevalence and progression of age-related macular degeneration: the CHARM study , 2008, BMC ophthalmology.

[30]  L. Boxt.  McDonald's blood flow in arteries , 1991, CardioVascular and Interventional Radiology.

[31]  A. Ramé.  [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.

[32]  C. Vlachopoulos,et al.  Acute Systemic Inflammation Increases Arterial Stiffness and Decreases Wave Reflections in Healthy Individuals , 2005, Circulation.

[33]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[34]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.